seal_of_the_united_states_department_of_veterans_affairs_1989-2012-svg

FOR IMMEDIATE RELEASE:

United States Department of Veterans Affairs Awards Molecular Testing Labs™ Federal Supply Schedule Contract

Pharmacogenomic testing is available to help guide clinicians’ medication decisions for veterans being treated for addiction management, mental health (including post-traumatic stress disorder) and chronic pain management

Vancouver, WA – December 15, 2016 – Molecular Testing Labs™ today announced that the U.S. Department of Veterans Affairs (VA) has awarded a Federal Supply Schedule (FSS) contract as a government supplier, effective December 15, 2016. The Veterans Health Administration is America’s largest integrated health care system serving 8.92 million enrolled patients at 1270 sites of care (2013 data).

Molecular Testing Labs’ Pharmacogenomic Test analyzes how an individual’s genetic makeup affects response to a number of medications used to treat such conditions as drug of abuse management, mental health (anxiety, bipolar disorder, depression, post-traumatic stress disorder and schizophrenia) and chronic pain management. Every medication reported carries Level I or II evidence from the CPIC or meets our internal criteria as defined by clinical studies (number of patients enrolled, p-value, odds ratio or DSM-V criteria from the American Psychiatric Association).

“We are steadfast in our commitment to help all veterans that have served this country”, said David DeLong, Co-Owner and US Army Veteran. “Understanding each patient’s genetic makeup can provide enormous support to the physicians that are treating serious, debilitating disease. There is a strong body of literature that speaks to the importance of understanding patient variability to medication as dictated by our own DNA.”

In the area of mental health, the National Center for Post-Traumatic Stress Disorder has estimated the following numbers for veterans who served in the Gulf War (Desert Storm): about 12 out of every 100 Gulf War Veterans (or 12%) have PTSD in a given year. Operations Iraqi Freedom (OIF) and Enduring Freedom (OEF): about 11-20 out of every 100 Veterans (or between 11-20%) who served in OIF or OEF have PTSD in a given year. Vietnam War: About 15 out of every 100 Vietnam Veterans (or 15%) were currently diagnosed with PTSD at the time of the most recent study in the late 1980s, the National Vietnam Veterans Readjustment Study (NVVRS). It is estimated that about 30 out of every 100 (or 30%) of Vietnam Veterans have had PTSD in their lifetime.

“Understanding what medication will work best for a patient with PTSD is one area where our organization can offer support”, said Adam Blackwell, Co-Owner and US Navy Veteran. “Testing from Molecular Testing Labs carries accreditation by the College of American Pathologists (CAP) and is unequivocally the most competitive offering on the market today, in terms of number of genetic variants analyzed vs. the price established for the VA. We wanted to put the best possible offering in the VA’s hands and we accomplished our goal.”

The VA FSS (V797D-70048) approval will also allow clinicians in the Department of Defense, the Bureau of Indian Affairs, and the Federal Bureau of Prisons to have access to Molecular Testing Labs’ pharmacogenomic tests.

Further insight into Molecular Testing Labs’ FSS Award: Testing is available in all 50 states, the District of Columbia and Puerto Rico. Individual product offerings include:

• Comprehensive Genetic Panel (PCR with Allele – Specific Probes & ARMS Test Methods). Includes 28 genetic markers related to the activation/metabolism of drug therapies and information related to risk of disease manifestation.
• Cystic Fibrosis (CF) Genetic Panel (PCR with Allele – Specific Probes Test Method). This is a comprehensive screening that provides analysis of 60 genetic markers. CF Testing is recommended for completion by all women of childbearing age, preferably before conception, by the American Congress of Obstetricians and Gynecologists (ACOG) and the American College of Medical Genetics and Genomics (ACMG).
• Urine Drug Screen Qualitative Panel (EIA Test Method). Covers seven classes of drugs and detects traces to minimal nanograms per milliliter.
• Comprehensive Urine Toxicology Panel (LC-MS/MS Test Method). Specific information related to the detection of drug therapies and confirmation of analytes and metabolites.
• My Home STD Test. Our direct-to-consumer at-home STD collection kit tests for seven of the most common sexually transmitted infections and is currently under review for FDA approval. Other test options include triple-site testing for Chlamydia, Gonorrhea, and Human Papilloma Virus.

More About Molecular Testing Labs
Molecular Testing Labs™ is a CLIA and CAP accredited, state-of-the-art, esoteric and reference laboratory. We specialize in high-complexity, molecular testing with an extensive portfolio of services including infectious disease, toxicology, targeted sequencing, single nucleotide polymorphism (SNP) genotyping, Next-Generation Sequencing (NGS), and high resolution immune profiling. Molecular Testing Labs offers a variety of clinical trial services comprising of assay development, trial site training, investigator support, and customized reporting.
We apply the maximum level of control to obtain the most consistent and highest quality results. Molecular Testing Labs is founded on three guiding principles – Compliance, Innovation and Partnership. For more information, please visit our corporate website – www.moleculartestinglabs.com

Contact:
Molecular Testing Labs
14401 SE 1st St,
Vancouver, WA 98684
Ph: 360-693-8850
www.moleculartestinglabs.com